European Organisation For Research And Treatment Of Cancer
European Organisation For Research And Treatment Of Cancer is recorded as a service provider in 19 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 19 of 19 trials · Latest update first
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
Sponsor BeOne Medicines I GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy - EMN17/54767414MMY3014
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
Sponsor Nuvation Bio Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL 1L)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Trial of Fianlimab (REGN3767, Anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG)
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Randomized Study To Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Combined with Chemotherapy versus Rituximab Combined with Chemotherapy in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-2)
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.
Sponsor Protara Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for European Organisation For Research And Treatment Of Cancer?
The 2026-10-09 snapshot links European Organisation For Research And Treatment Of Cancer to 19 distinct CTIS trials. Recorded services include Clinical outcome assessments, (1) the EORTC Questionnaires version 3.0 for the above-mentioned Study in the currently available languages, and (2) the standard algorithms for scoring the EORTC Questionnaires, Biomarker Testing, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for European Organisation For Research And Treatment Of Cancer?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Haematological Malignancies, Gastroenterology, Nutrition. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to European Organisation For Research And Treatment Of Cancer conducted?
The linked trials record locations in 21 countries, including Spain, France, Germany, Italy, Poland. These are trial locations, not confirmed office locations or countries where European Organisation For Research And Treatment Of Cancer delivered services.
What can this page tell me about European Organisation For Research And Treatment Of Cancer's trial experience?
Browse 19 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under European Organisation For Research And Treatment Of Cancer. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- European Organisation For Research And Treatment Of Cancer
- European Organisation for Research and Treatment of Cancer